Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.

× No keyword cloud information.

22 in total

1. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma.

Authors: D Lienard; P Ewalenko; J J Delmotte; N Renard; F J Lejeune
Journal: J Clin Oncol Date: 1992-01 Impact factor: 44.544

2. Selective targeting of angiogenic tumor vasculature by vascular endothelial-cadherin antibody inhibits tumor growth without affecting vascular permeability.

Authors: Fang Liao; Jacqueline F Doody; Jay Overholser; Bridget Finnerty; Rajiv Bassi; Yan Wu; Elisabetta Dejana; Paul Kussie; Peter Bohlen; Daniel J Hicklin
Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701

3. A permissive role for tumor necrosis factor in vascular endothelial growth factor-induced vascular permeability.

Authors: M Clauss; C Sunderkötter; B Sveinbjörnsson; S Hippenstiel; A Willuweit; M Marino; E Haas; R Seljelid; P Scheurich; N Suttorp; M Grell; W Risau
Journal: Blood Date: 2001-03-01 Impact factor: 22.113

4. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability.

Authors: D Fukumura; T Gohongi; A Kadambi; Y Izumi; J Ang; C O Yun; D G Buerk; P L Huang; R K Jain
Journal: Proc Natl Acad Sci U S A Date: 2001-02-27 Impact factor: 11.205

5. Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.

Authors: T L Ten Hagen; A H Van Der Veen; P T Nooijen; S T Van Tiel; A L Seynhaeve; A M Eggermont
Journal: Int J Cancer Date: 2000-09-15 Impact factor: 7.396

Review 6. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis.

Authors: I J Fidler
Journal: Surg Oncol Clin N Am Date: 2001-04 Impact factor: 3.495

7. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.

Authors: Flavio Curnis; Angelina Sacchi; Angelo Corti
Journal: J Clin Invest Date: 2002-08 Impact factor: 14.808

8. TNF-alpha augments intratumoural concentrations of doxorubicin in TNF-alpha-based isolated limb perfusion in rat sarcoma models and enhances anti-tumour effects.

Authors: A H van der Veen; J H de Wilt; A M Eggermont; S T van Tiel; A L Seynhaeve; T L ten Hagen
Journal: Br J Cancer Date: 2000-02 Impact factor: 7.640

9. Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion.

Authors: J H de Wilt; T L ten Hagen; G de Boeck; S T van Tiel; E A de Bruijn; A M Eggermont
Journal: Br J Cancer Date: 2000-03 Impact factor: 7.640

10. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinases.

Authors: J Wu; T Akaike; K Hayashida; T Okamoto; A Okuyama; H Maeda
Journal: Jpn J Cancer Res Date: 2001-04

16 in total

1. Gene expression polymorphisms of interleukins-1 beta, -4, -6, -8, -10, and tumor necrosis factors-alpha, -beta: regression analysis of their effect upon oral squamous cell carcinoma.

Authors: Eleftherios Vairaktaris; Christos Yapijakis; Zoe Serefoglou; Dimitrios Avgoustidis; Elena Critselis; Sofia Spyridonidou; Antonis Vylliotis; Spyridoula Derka; Stavros Vassiliou; Emeka Nkenke; Efstratios Patsouris
Journal: J Cancer Res Clin Oncol Date: 2008-02-14 Impact factor: 4.553

2. Genetic variants in TNF-α promoter are predictors of recurrence in patients with squamous cell carcinoma of oropharynx after definitive radiotherapy.

Authors: Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Xicheng Song; Peng Wei; Lei Jin; Li Chao; Qingyi Wei; Guojun Li
Journal: Int J Cancer Date: 2013-10-24 Impact factor: 7.396

Review 3. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor.

Authors: Yinghuan Li; Jie Wang; M Guillaume Wientjes; Jessie L-S Au
Journal: Adv Drug Deliv Rev Date: 2011-05-03 Impact factor: 15.470

4. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.

Authors: Lesley D McPhail; Dominick J O McIntyre; Christian Ludwig; Philip Kestell; John R Griffiths; Lloyd R Kelland; Simon P Robinson
Journal: Neoplasia Date: 2006-03 Impact factor: 5.715

5. A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Authors: Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Journal: Oncoimmunology Date: 2017-11-27 Impact factor: 8.110

6. TNF-α promoter polymorphisms and risk of recurrence in patients with squamous cell carcinomas of the nonoropharynx.

Authors: Caiyun Zhang; Erich M Sturgis; Hongliang Zheng; Mark E Zafereo; Qingyi Wei; Guojun Li
Journal: Int J Cancer Date: 2014-02-27 Impact factor: 7.396

Review 7. Redox-mediated and ionizing-radiation-induced inflammatory mediators in prostate cancer development and treatment.

Authors: Lu Miao; Aaron K Holley; Yanming Zhao; William H St Clair; Daret K St Clair
Journal: Antioxid Redox Signal Date: 2014-01-22 Impact factor: 8.401

Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability.